PAION

PAION is a publicly listed specialty pharmaceutical company headquartered in Aachen, Germany, that develops and markets innovative drugs for hospital-based sedation, anesthesia, and critical care. Its flagship product, remimazolam (Byfavo®), is an ultra-short-acting, controllable benzodiazepine sedative/anesthetic approved in the U.S., EU, China, South Korea, Japan, and other regions, and is being rolled out across selected European markets. The company also offers Angiotensin II (GIAPREZA®) for refractory hypotension in septic shock and eravacycline (XERAVA®), a novel fluorocycline antibiotic for complicated intra-abdominal infections. By focusing on novel, high-impact therapeutics that improve patient outcomes and operational efficiency, PAION aims to be a leading specialty pharma player in anesthesia and critical care.